Skip to content

The efficacy and safety of remimazolam besylate in mechanical ventilated patients in intensive care unit: a multi-center prospective randomized control trial

The efficacy and safety of remimazolam besylate in mechanical ventilated patients in intensive care unit: a multi-center prospective randomized control trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049447
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical ventilated patients requiring sedation in the ICU

Interventions

Experimental group:Sedation with remazolam besylate
Control group:Sedation with dexmedetomidine

Sponsors

Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old; 2. Accept invasive mechanical ventilation; 3. It is expected that the extubation condition cannot be reached within 48 hours; 4. Need to use sedative drugs to ensure comfort, safety and to promote the implementation of life support measures; 5. Subjects or their authorized principals gave informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation; 2. Patients who need deep sedation to assist special treatments such as prone position and muscle relaxants; 3. Has been intubated in the ICU (excluding intubation time in the operating room or transport) for more than 12 hours; 4. MAP pressure <50 mmHg after adequate fluid resuscitation and vasopressor therapy; 5. Heart rate < 55 beats/min, except for patients who are receiving beta-blockers or advanced atrioventricular block therapy without a functional pacemaker; 6. Confirmed or suspected spinal cord injury or other pathological conditions that may lead to permanent or long-term debilitation; 7. Cardiac insufficiency, left ventricular EF<=30%; 8. Severe craniocerebral injury, Glasgow score (GCS) < 8; 9. Liver function damage (Child-Pugh C level); 10. Renal insufficiency (acute: AKI grade 3, chronic: CKD stage 3 and above); 11. The patient is in critical condition and has a poor prognosis, and the patient or authorized client gave up treatment before the start of the trial; 12. Myasthenia gravis patients; 13. Patients with bronchial asthma; 14. Allergic to the research drug or ingredient; 15. The patient participates in other clinical trial studies.

Design outcomes

Primary

MeasureTime frame
The effective rate of sedation within 48 hours of randomization;

Secondary

MeasureTime frame
Vital signs;the time of mechanical ventilation;

Countries

China

Contacts

Public ContactShao Huanzhang

Henan Provincial People's Hospital

shaohuanzhang@sina.com+86 18538297681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026